Aesica Appoints New Product Release Manager
Aesica has appointed Adam Burgess to the position of Product Release Manager. Adam’s wide ranging role includes managing the Qualified Persons team; directing and controlling QP activities in line with operational requirements, the role also involves the development of quality systems, product release, facilitating process improvements and acting as a Qualified Person.
Based at Queenborough, UK Adam has responsibility for pharmaceutical quality assurance across the Kent-based site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organisational structures. Adam reports directly to Christine Ernst, the Site Head of Quality at Aesica, Queenborough, UK.
Previously, he held the position of Manager, Defective Medicines Report Centre and Import Notification at the MHRA and was an active Qualified Person at Martindale Pharma. Prior to that, he worked as a QA Manager in Preclinical Quality Assurance at GlaxoSmithKline. His expertise reaches across both commercial and clinical trial products including steriles, non-sterile tablets, capsules and liquids. Adam brings QA experience in laboratory, packaging and manufacturing area settings. He has strong skills in the risk assessment of pharmaceutical products and has authored position papers focused both on product quality and patient safety implications of unplanned events.
Remarking on his new position, Adam Burges said: “I am delighted to be appointed to this role at Aesica. It affords me the opportunity to return to pharmaceutical manufacturing and packaging, bringing the experience that I have gained at the UK regulator. This experience will help me to further enhance and drive quality culture initiatives across the company — in particular at Queenborough. I am looking forward to leading the product release team to ensure that all staff fully understand customer needs, consistently deliver results, whilst maintaining the high quality levels demanded and expected.”
Commenting on Adam Burgess’s appointment, Indira Walker, Corporate Quality Director at Aesica remarked: “We are delighted that Adam has joined our QA team. He brings strong QA expertise and we are especially impressed by his combined experience of working both for prominent pharmaceutical companies and the MHRA regulatory authority.”
She continued: “We look forward to Adam contributing significantly to making further inroads into driving up QA standards so that we deliver the most consistent and best-in-class quality of service within the industry.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.